Audentes Therapeutics (NASDAQ:BOLD) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.07, Briefing.com reports. During the same period last year, the firm earned ($0.97) EPS.
Shares of NASDAQ BOLD traded up $1.49 during trading on Friday, reaching $28.57. The company had a trading volume of 614,500 shares, compared to its average volume of 490,503. The stock has a market capitalization of $1.24 billion, a PE ratio of -8.40 and a beta of 1.77. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $41.65. The stock has a 50-day moving average price of $28.15 and a two-hundred day moving average price of $34.34.
Several brokerages recently issued reports on BOLD. Robert W. Baird began coverage on Audentes Therapeutics in a report on Wednesday, October 2nd. They set an “underperform” rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of Audentes Therapeutics in a report on Friday. ValuEngine cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $40.76.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Read More: What is the market perform rating?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.